Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

OBJECTIVES:

Primary

- To evaluate the effect of erlotinib and stereotactic body radiotherapy on 6-month
progression-free survival of patients with locally advanced or metastatic non-small cell
lung cancer.

Secondary

- To describe the actuarial rate of in-field local control and out-of-field disease
progression in patients treated with this regimen.

- To evaluate the safety of this regimen in these patients.

- To evaluate overall survival of patients treated with this regimen.

- To evaluate the duration of erlotinib usage and time to initiation of third-line
systemic therapy (chemotherapy or biologic agent) in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral erlotinib hydrochloride once daily in the absence of disease
progression or unacceptable toxicity. Beginning 1-4 weeks after the initiation of erlotinib
hydrochloride, patients undergo stereotactic body radiotherapy.

After completion of study treatment, patients are followed every 3 months.

Inclusion Criteria

Patients must meet all of the following inclusion criteria to be eligible for participation
in this study:

1. Patients must have biopsy proven NSCLC that is locally advanced or metastatic.

2. Patients must have had failure of at least one prior chemotherapy regimen.

3. Patients must not have started erlotinib therapy more than 4 weeks prior to the
initiation of SBRT.

4. Age ≥ 18 years

5. Patients must have measurable disease at baseline.

6. Patients can have up to only 6 discrete active extracranial lesions (≤3 in the liver
and ≤3 in the lung) identified by PET scan and also seen on correlative plain film, CT
scan, or MRI within 8 weeks prior to the initiation of SBRT.

1. For patients who have received prior radiotherapy to the primary site in the
lung, residual PET activity is difficult to interpret and will not be considered
a site of active disease if the CT appearance is stable or improved over an
interval of at least three months

2. Patients who previously received radiotherapy to the primary site will be
ineligible if there is CT evidence of disease progression within the past 3
months.

3. Patients with previously un-irradiated primary sites will be potentially
eligible, but special considerations apply (section 4.3.2).

4. Up to 2 contiguous vertebral metastases will be considered a single site of
disease.

7. Patients must have a KPS >60

8. AST, ALT & Alkaline phosphates must be ≤ 2.5X the upper limit of normal. Total
bilirubin must be within the limit of normal.

9. Patients should have adequate bone marrow function as defined by peripheral
granulocyte count of ≥1500/mm³.

10. Patients should have adequate renal function (serum creatinine ≤1.5 times the ULN).

11. Females of childbearing potential should have a negative pregnancy test.

12. Patients who would be receiving SBRT for lung tumors who are known or suspected by the
treating radiation oncologist to have compromised lung function must have a documented
forced expiratory volume in 1 second (FEV1) ≥ 1L.

13. Patients must provide verbal and written informed consent to participate in the study.

14. Total bilirubin: within normal institutional limits

Exclusion Criteria Patients who meet any of the following exclusion criteria are not to be
enrolled in this study.

1. Patients who previously received radiotherapy to the primary site with CT evidence of
disease progression at the primary site within 3 months following the initial
radiotherapy.

2. Patients with either untreated brain metastases or brain metastases treated within the
past three months are ineligible

3. Patients with serious, uncontrolled, concurrent infection(s).

4. Significant weight loss (>10%) in the prior 3 months.

5. Because the tolerance dose of SBRT to the gastrointestinal tract is not established,
patients with metastatic disease invading the esophagus, stomach, intestines, or
mesenteric lymph nodes will not be eligible.

6. Patients with cutaneous metastasis of NSCLC.

7. Treatment for other carcinomas within the last five years, except cured non-melanoma
skin and treated in-situ cancers.

8. Patients with more than 6 discrete extra-cranial lesions.

9. Participation in any investigational drug study within 4 weeks preceding the start of
study treatment.

10. Unwillingness to participate or inability to comply with the protocol for the duration
of the study.

11. Patients who are pregnant. Patients with reproductive capability will need to use
adequate contraception during the time of participation in the study.

12. Patients who have had prior EGFR inhibitors.